The study was designed to analyze the efficacy and safety of anti-PD-1/PD-L1 antibodies for the treatment of advanced solid tumors.
The study is a real-world study and the case records of patients with advanced solid tumors who visited Department of Medical Oncology, Chinese PLA General Hospital from 2015 to 2019 and received anti-PD-1/PD-L1 antibody therapy will be collected in this study. The medical data including patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, and so on will be extracted to analyze the effectivity and safety of anti-PD-1/PD-L1 antibodies and explore the prognosis-relevant factors of advanced solid tumors.
Study Type
OBSERVATIONAL
Enrollment
400
The study is a real-world study. According to the actual medical history of patients, the usage of anti-PD-1/PD-L1 antibodies was collected.
Chinese PLA General Hospital
Beijing, China
RECRUITINGProgression-free survival (PFS)
PFS was defined as the length of time from the administration of the first-dose until disease progression or death from any cause before disease progression.
Time frame: 6 months
Rate of adverse events (AEs)/ serious adverse events (SAEs) in patients with advanced solid tumors receiving anti-PD-1/PD-L1 antibody therapy.
AEs/SAEs were evaluated using NCI-CTCAE v5.0
Time frame: up to 4 weeks after the last dose
Objective Response Rate (ORR)
ORR was defined as the percentage of patients with complete response (CR) and partial response (PR) according to Response Evaluation Criteria in Solid Tumours (RECIST).
Time frame: 6 months
Disease Control Rate (DCR)
DCR was defined as the percentage of patients with complete response (CR), partial response (PR) and stable disease (SD) according to Response Evaluation Criteria in Solid Tumours (RECIST).
Time frame: 6 months
Overall survival (OS)
OS was defined as the length of time from the administration of the first-dose until death from any cause.
Time frame: up to 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.